# A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

> **NCT07463183** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 100 (estimated)

## Conditions studied

- Colitis Ulcerative
- Ulcerative Colitis

## Interventions

- **DRUG:** MK-8690
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07463183
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2027-10-28
- **Final completion:** 2028-12-21
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07463183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07463183, "A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07463183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*